Skip to main content

Table 4 Serious adverse events (SAEs)

From: Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer

 

Lapatinib + vinorelbine (N=44)

Subjects with any SAE, n (%)

22 (50)

With2 (5%) patients,n(%)

 

 Neutropenia

15 (34)*

 Diarrhea

3 (7)

 Febrile neutropenia

3 (7)

 Abdominal pain

2 (5)

 Dehydration

2 (5)

Drug-related fatal SAEs, n (%)

0 (0)

  1. *Grade 4 laboratory abnormalities were protocol defined as SAEs.